Technology policy and social policy: How industrial policy applies to health

International Handbook on Industrial Policy

Volumn , Issue , 2006, Pages 298-317

  Paci, Daniele ^a   Schweitzer, Stuart O ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73649106259     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (47)

1. Arrow, K.J. (1962), 'Economic welfare and the allocation of resources for invention', in R.R. Nelson (ed.), The Rate and Direction of Innovative Activity: Economic and Social Factors, Princeton: Princeton University Press.
2. Barr, N. (1998), The Economics of the Welfare State, Oxford and New York: Oxford University Press.
3. Becker, G.S. (1993), Human Capital, 3rd edn, Chicago: University of Chicago Press.
4. Bianchi, P. (1996), 'New approach to industrial policies at the local level', in F. Cossentino, F. Pyke and W. Sengenberger (eds), Local and Regional Response to Global Pressure: The Case of Italy and its Industrial Districts, Geneva: International Institute for Labour Studies, Research Series no. 103, pp.195-206.
5. Buchanan, D.R. (2000), An Ethic For Health Promotion. Rethinking the Sources of Human Well-Being, Oxford and New York: Oxford University Press.
6. Chang, H. (1994), The Political Economy of Industrial Policy, New York: St Martin's Press.
7. Cohen, M., R.R. Nelson and J.P.Walsh (2000), 'Protecting their intellectual assets: appropriability conditions and why firms patent and why they do not in the American manufacturing sector', NBER working paper no. 7552.
8. Comanor, W.S. and S.O. Schweitzer (1995), 'Pharmaceuticals', in W. Adams and J. Brock (eds), The Structure of American Industry, 9th edn, Englewood Cliffs, NJ: Prentice-Hall.
9. Corden, W.M. (1997), Trade Policy and Economic Welfare, 2nd edn, Oxford: Clarendon Press.
10. David, P. (2004), 'Can "open science" be protected from the evolving regime of intellectual property rights protection?', Journal of Theoretical and Institutional Economics, 160, 1-26.
11. Di Masi, J.A., R.W. Hansen and H.G. Grabowski (2003), 'The price of innovation: new estimates of drug development costs', Journal of Health Economics, 22, 151-85.
12. Di Tommaso, M.R. and S.O. Schweitzer (2005), 'Introduction: why apply industrial policy to the health industry?', in M.R. Di Tommaso and S.O. Schweitzer (eds), Health Policy and High-tech Clusters Industrial Development. Learning from Innovation in the Health Industry, Cheltenham, UK and Northampton, MA, USA: Edward Elgar, pp.3-16.
13. Di Tommaso, M.R., D. Paci and S.O. Schweitzer (2005), 'The geography of intangibles, the case of the health industry', in M.R. Di Tommaso and S.O. Schweitzer (eds), Health Policy and High-tech Industrial Development. Learning from Innovation in the Health Industry, Cheltenham, UK and Northampton, MA, USA: Edwar Elgar, pp.258-78.
14. Feldstein, P.J. (2001), Health Care Economics, 6th edn, Albany, NY: Delmar Publishers.
15. Feldstein, P.J. (2002), Health Policy Issues. An Economic Perspective, 3rd edn,Washington, DC: AUPHA Press.
16. Folland, S., A.C. Goodman and M. Stano (2001), The Economics of Health and Health Care, 3rd edn, Upper Saddle River, NJ: Prentice-Hall.
17. Grossman, M. (1972), 'On the concept of health capital and the demand for health', Journal of Political Economy, 80, 223-55.
18. International Monetary Fund-IMF (2004), The Macroeconomics of Aids,Washington, DC: IMF Publications.
19. Ioannides-Demos, L.L., J.E. Ibrahim and J.J. McNeil (2002), 'Reference based pricing schemes: effects on pharmaceutical expenditure, resource utilisation, and health outcomes', Pharmacoeconomics, 20( 9), 577-91.
20. Lall, S. and M. Teubal (1988), ' "Market stimulating" technology policies in developing countries: a framework with examples from East Asia', World Development, 26(8).
21. Levin, R.,W. Cohen and D. Mowery (1987), 'R&D appropriability, opportunity and market structure: new evidence on some Schumpeterian hypotheses', American Economic Review, papers and proceedings, 75, 20-24.
22. Mansfield, D. (1986), 'Patents and innovation: an empirical study', Management Science, 32, 173-81.
23. National Cancer Institution-Division of Cancer Treatment (1995), Program Information Booklet.
24. The National Institute for Health Care Management Research and Education Foundation (2001), 'The changing pattern of pharmaceutical innovation', research report, Washington, DC.
25. Nelson, R.R. (2003), 'The market economy and the scientific commons', Research Policy, 33, 455-71.
26. Newhouse, J.P. (1993), Free For All, Lessons from the RAND Health Insurance Experiment, Cambridge, MA: Harvard University Press.
27. OECD (2002), OECD Health Data, Paris.
28. OECD (2003), OECD Health Data, Paris.
29. Pavitt, K. (1998), 'The social shaping of the national science base', Research Policy, 27, 793-805.
30. Phrma-Association of pharmaceutical manufacturers of America (2003), Pharmaceutical Industry Profile.
31. Prevezer, M. (1997), 'The dynamics of industrial clustering in biotechnology', Small Business Economics, 9, 255-71.
32. Scherer, F.M. and S.Weisburst (1995), 'Economic effects of strengthening pharmaceutical patent protection in Italy', International Review of Industrial Property and Copyright Law, 26, 1009-24.
33. Schulenberg, M. (1994), 'The German health care system at the crossroads', Health Economics, 3(5), 301-4.
34. Schweitzer, S.O. (1997), Pharmaceutical Economics and Policy, New York: Oxford University Press.
35. Schweitzer, S.O. and M.R. Di Tommaso (2005), 'The health industry model: New Roles for the Health Industry', in M.R. Di Tommaso and S.O. Schweitzer (eds), Health Policy and High-tech Clusters Industrial Development. Learning from Innovation in the Health Industry, Cheltenham, UK and Northampton, MA, USA: Edward Elgar, pp.17-45.
36. Schweitzer, S.O., J. Connell and F.P. Schoenberg (2005), 'Clustering in the biotechnology industry', in M.R. Di Tommaso and S.O. Schweitzer (eds), Health Policy and High-tech Industrial Development. Learning from Innovation in the Health Industry, Cheltenham, UK and Northampton, MA, USA: Edwar Elgar, pp.258-78.
37. Sen, A. (1999), Development as Freedom, Oxford: Oxford University Press.
38. Soumerai, S.B., D. Ross Degnan, J. Avorn, T.J. Mclaughlin and I. Choodnovskiy (1991), 'Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes', New England Journal of Medicine, 325(15), 1072-7.
39. Soumerai, S.B., D. Ross Degnan, J. Avorn, T.J. Mclaughlin and I. Choodnovskiy (1994), 'Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia', New England Journal of Medicine, 331(10), 650-55.
40. Stewart-Brown, S., R. Surender, J. Bradlow, A. Coulter and H. Doll (1995), 'The effects of fundholding in general practice on prescribing habits three years after the introduction of the scheme', British Medical Journal, 311(9), 1543-7.
41. Stiglitz, J. (1999), 'Knowledge as a public good', in E.Kaul, I.E. Grunberg and M.A. Stern, Global Public Goods, New York: Oxford University Press.
42. Taylor, C. and Z. Silberston (1973), The Economic Impact of the Patent System: A Study of the British Patent System, Cambridge, MA: Cambridge University Press.
43. The National Institute for Health Care Management Research and Educational Foundation (2002), 'Changing patterns of pharmaceutical innovation' (http://www.nihcm.org).
44. Walley T.,M. Murphy, M. Codd, Z. Johnston and T. Quirke (2000), 'Effects of monetary incentives on primary care prescribing in Ireland: changes in prescribing patterns in one health board, 1990-95', Pharmacoepidemiology and Drug Safety, 9(7), 591-8.
45. World Health Organization-WHO (1948), Preamble to the constitution of the World Health Organization as adopted by the International Health Conference,New York, 19-22 June 1946; signed on 22 July 1946, entered into force on 7 April 1948.
46. World Health Organization-WHO (2001), Macroeconomics and Health: Investing in Health for Economic Development, Report of the Commission on Macroeconomics and Health Geneva, World Health Organization.
47. World Health Organization-WHO (2005), World Health Report 2005.